Todd Franklin Watanabe
Principal executive officer pay for Todd Franklin Watanabe, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Arcutis Biotherapeutics, Inc. (ARQT) FY2020–FY2025
Lagged peersTSR -20% vs peer group -10% over FY2020–FY2025
Paid for declineCAP $16,770,089→$20,353,965 while $100 invested went $129.04→$103.23 (FY2020–FY2025)
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2020 | $2.8M | $16.8M |
| FY2021 | $4.8M | $441,904 |
| FY2022 | $4.6M | $2.4M |
| FY2023 | $4.9M | -$1.2M |
| FY2024 | $3.7M | $11.2M |
| FY2025 | $7.2M | $20.4M |
The company's "$100 invested" index ran $129.04 at FY2020 → $103.23 by FY2025 — an annualized return of -4.4%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: -4.4%/yr at ARQT ( FY2020–FY2025). See the CEO track-record ranking for context.